Share

January 2021; 8 (1) ArticleOpen Access

Overweight/obesity in young adulthood interacts with aspects of EBV infection in MS etiology

Anna Karin Hedström, Nicole Brenner, Julia Butt, Jan Hillert, Tim Waterboer, Tomas Olsson, Lars Alfredsson
First published December 15, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000912
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
903

Share

Article Information

vol. 8 no. 1 e912
DOI: 
https://doi.org/10.1212/NXI.0000000000000912
PubMed: 
33465039
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 20, 2020
  • Accepted in final form September 11, 2020
  • First Published December 15, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author Disclosures

    1. Anna Karin Hedström, MD, PhD,
    2. Nicole Brenner, PhD (nicole.brenner{at}dkfz-heidelberg.de),
    3. Julia Butt, PhD (j.butt{at}dkfz-heidelberg.de),
    4. Jan Hillert, MD, PhD (jan.hillert{at}ki.se),
    5. Tim Waterboer, PhD (t.waterboer{at}dkfz-heidelberg.de),
    6. Tomas Olsson, MD, PhD* (tomas.olsson{at}ki.se) and
    7. Lars Alfredsson, PhD* (lars.alfredsson{at}ki.se)
  1. Anna Karin Hedström, MD, PhD,
    2. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Nicole Brenner, PhD (nicole.brenner{at}dkfz-heidelberg.de),
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Julia Butt, PhD (j.butt{at}dkfz-heidelberg.de),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Jan Hillert, MD, PhD (jan.hillert{at}ki.se),
    5. Scientific Advisory Boards:

    1. Dr Hillert received honoraria for serving on advisory boards for BiogenIdec, Celgene, Merck, Sanofi-Genzyme, Novartis and Sandoz

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Received travel expenses and/or honoraria for lectures or educational activities for BiogenIdec, Merck-Serono, Novartis, Sanofi-Genzyme and TEVA

    Editorial Boards:

    1. J Neuroimmunology, no compensation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr Hillert research on MS is currently supported by Biogen, Celgene, Novartis, Merck, Roche and Sanofi-Genzyme. In the past Dr Hillert has also received unrestricted research grants from Merck-Serono and Bayer-Schering.

    Research Support, Government Entities:

    1. Dr Hillert receives research support from the Swedish Research Council from 2019 to 2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dr Hillert research on MS is supported by the Swedish Brain Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Tim Waterboer, PhD (t.waterboer{at}dkfz-heidelberg.de),
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Tomas Olsson, MD, PhD* (tomas.olsson{at}ki.se) and
    7. Scientific Advisory Boards:

    1. Advisory boards Biogen 2006- 2020 and Genzyme 2006- 2020, Merck 2016-2020, Roche and Almirall. Novartis 2009-2018. Cellgene 2019 With all of them advice with regard to therapy in multiple sclerosis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. For lectures on Multiple sclerosis, Novartis 2008 and BiogenIdec 2006, 2007, 2008, 2009, 2010 , 2011, 2012 and 2016. Merck 2019. Genzyme 2012 Merck 2017-2020

    Editorial Boards:

    1. Co-editor 2006 in Current opinion in Immunology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1)Merck, 2)Biogen, 3)Genzyme, 4) Novartis, 5) Roche and 6) Merck, all for unrestricted MS research.

    Research Support, Government Entities:

    1. Tomas Olsson (TO) has received grant support from The Swedish Research council (07488), EU fp7, Neurinox 2012-2016 and combiMS, 2013-2014, Swedish Brain foundation, Knut and Alice Wallenberg foundation.Margareta af Ugglas foundation

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Swedish Brain foundation TO has also received unrestricted research grants from AstraZeneca.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Lars Alfredsson, PhD* (lars.alfredsson{at}ki.se)
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speakers honoraria from Teva and Biogen Idec

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Swedish Medical Research Council (K2013-69X-14973-10- 4,2013-2016, Dnr 825-2012-5168, 2013-2015, Dnr 2016- 02349, 2017-2020) and Swedish Council for Working life, Health and Welfare (Dnr 2012-0325,2013-2015, Dnr 2013- 0194 and 2013-0710, 2014-2016, Dnr 2015-00195,2016- 018, 2017-00687), AFA insurance (Dnr 120299, 2013-2016, 160361), Stockholm County Council (Dnr 2016-1376, 2018- 0201)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Swedish Brain Foundation (FO2015—0051, FO2016-2017, FO2017- 0076, FO2019-006, FO2020-0077)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Clinical Neuroscience (A.K.H., J.H., T.O., L.A.), Karolinska Institutet, Stockholm, Sweden; Infections and Cancer Epidemiology (N.B., J.B., T.W.), German Cancer Research Center (DKFZ), Heidelberg; Center for Molecular Medicine (J.H., T.O.), Karolinska Institutet at Karolinska University Hospital, Solna, Sweden; and Institute of Environmental Medicine (L.A.), Karolinska Institutet, Stockholm, Sweden.
  1. Correspondence
    Dr. Hedström anna.hedstrom{at}ki.se
View Full Text

Article usage

Article usage: December 2020 to August 2023

AbstractFullPdfSource
Dec 20203129131Highwire
Jan 202134715123Highwire
Feb 20211853357Highwire
Mar 2021625335Highwire
Apr 202144618Highwire
May 2021311724Highwire
Jun 202135222Highwire
Jul 202144625Highwire
Aug 202165616Highwire
Sep 2021295444Highwire
Oct 202197142Highwire
Nov 202113926Highwire
Dec 202144437Highwire
Jan 202289428Highwire
Feb 2022144926Highwire
Mar 202295029Highwire
Apr 202215947Highwire
May 202254216Highwire
Jun 202225534Highwire
Jul 202225513Highwire
Aug 20224726Highwire
Sep 202246323Highwire
Oct 202227616Highwire
Nov 2022911427Highwire
Dec 202227218Highwire
Jan 202367913Highwire
Feb 2023310917Highwire
Mar 202348617Highwire
Apr 202325114Highwire
May 202345425Highwire
Jun 20233697Highwire
Jul 202385416Highwire
Aug 202384911Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles